Author Archives: Gastroenterology Journal

Obesity among patients with inflammatory bowel disease (IBD) is increasing with prevalence of 15-40%. Studies have shown that obesity may have poor prognostic implications on IBD treatment and outcomes. There is lack of data focused on the management o… Continue reading →

Extraintestinal Manifestations (EIMs) of Inflammatory Bowel Diseases (IBD) are a frequent feature of disease, occurring in 25-40% of patients with IBD. While associations with IBD type, gender, and age at diagnosis are known, less is known about the as… Continue reading →

Crohn’s perianal fistulas (CPFs) are a common complication in patients with Crohn’s disease. Stem cell therapies are under investigation for the treatment of CPF; however, understanding amongst healthcare professionals (HCPs) is unknown and their educa… Continue reading →

Pentosan polysulfate is used for symptomatic management of interstitial cystitis. At one institution we incidentally noted six patients who were on this agent and had a diagnosis of inflammatory bowel disease (IBD). Three of these patients stopped the … Continue reading →

Biosimilars are biologic products similar in safety and efficacy to the originator product. Tumor necrosis factor-alpha inhibitors (anti-TNFs) are used in the treatment of inflammatory bowel diseases (IBD). There are limited studies evaluating the long… Continue reading →

Crohn’s disease (CD) has been known to cause transmural inflammation of the gastrointestinal wall with manifestations including ulcers, abscesses, and fistula. Peptic ulcer disease (PUD) is most commonly caused by Non-Steroid Anti-Inflammatory Drugs (N… Continue reading →

Perianal fistulas occur in ∼30-40% of patients associated with high morbidity and an impaired quality of life. The management of perianal fistulizing CD is a major clinical challenge, where its underlying etiology of is poorly understood. Continue reading →

Given the increase in prevalence of Inflammatory Bowel Disease (IBD) worldwide and the increase in general population life expectancy, it is expected to for IBD to be more prevalent disorder among elderly patients. However, the mortality and outcomes o… Continue reading →

Very early onset inflammatory bowel disease (VEOIBD) is defined as disease onset prior to age 6. VEOIBD is monogenic in >5% of cases; however, in the remaining cases, molecular basis of disease is unknown. We aimed to utilize bulk RNA-seq of blood to 1… Continue reading →

Several risk factors have been associated with inflammatory bowel diseases (IBD), including genetic, environmental, gut microbiota and immune dysregulation. Psychiatric disorders have been linked to IBD. However, the question of whether psychiatric con… Continue reading →